This article reviews the definition of HCPs, risks posed by HCPs, regulatory concerns, commonly accepted ELISA methods for HCP measurement and their limitations, and orthogonal methods available for HCP characterization.
Fengqiang Wang, PhD
Advertisement
Fengqiang Wang, PhD, is associate principal scientist,Sterile Product and Analytical Development, Merck Research Laboratories, 2000 Galloping Hill Road, K15-4-E214Kenilworth, NJ 07033; fengqiang.wang@merck.com
Articles by Fengqiang Wang, PhD
Advertisement
Latest Updated Articles
Host-Cell Protein Measurement and ControlPublished: June 1st 2015 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
